

INDEX

Note: Entries followed by “f” indicate figures; “t” tables.

- Abscess, 14t, 51-52
 - clinical features of, 51
 - diagnosis of, 51
 - epidemiology and etiology of, 51
 - pathogens in, 51
 - reference resources for, 52
 - treatment and management of, 45-52, 46f-50f
- Acetic acid compresses, 84
- Acquired immunodeficiency syndrome. *See* AIDS (acquired immunodeficiency syndrome).
- Actinomyces* spp, 85
- Acute paronychia, 14t
- Acyclovir, 98-99, 100t-101t, 110-112, 111t
- Adenopathy, regional, 67-68
- Aeromonas hydrophila*, 63-64, 78
- AIDS (acquired immunodeficiency syndrome), 115-118
- Alastrim, 122
- Alcoholism, 61-62
- Allylamines, 142t-143t, 162t-163t
- Alternative antibiotic therapies, 46t-50t, 64. *See also* Antibiotic therapies.
- Aluminum chloride solution, 80, 85-86
- American Academy of Dermatology, 137
- Amikacin, 84
- Aminoglycosides, 15-16, 16t, 78, 83-84
- Amoxicillin/clavulanate, 24t-25t, 64
- Analgesics, 110-112
- Angioedema, 67-68
- Animal bites, 62-64
- Anti-DNAase titers, 67-68
- Antibiograms, local, 58-59
- Antibiotic therapies, 18t-19t. *See also under individual drug names and classes.*
 - alternative, 46t-50t, 64
 - amikacin, 84
 - aminoglycosides, 15-16, 16t, 78, 83-84
 - amoxicillin/clavulanate, 24t-25t, 64
 - antibacterial soaps, 55, 59, 80
 - azithromycin, 16-17, 73
 - aztreonam, 78
 - bacitracin, 26t-28t, 73
 - for bacterial infections, 13-27, 16t, 18t-20t, 21f-23f, 24t-28t
 - β -lactam drugs, 15-16, 46t-50t

Antibiotic therapies (*continued*)

carbapenems, 16t
cefaclor, 18t-19t
cefdinir, 16, 18t-19t, 23f, 24t-25t, 46t-50t
cefixime, 18t-19t
cefotaxime, 64, 84
cefepodoxime, 18t-19t, 24t-25t
cefprozil, 18t-19t, 24t-25t
ceftazidime, 84
ceftributen, 18t-19t
ceftriaxone, 64
cefuroxime, 18t-19t, 24t-25t
cephalexin, 18t-19t, 21f-22f, 24t-25t
cephalosporins, 15-16, 16t, 18t-19t, 22f, 33-35, 46t, 58-59, 63-64, 73
 extended-spectrum third-generation, 18t-19t, 23f, 46t-50t, 83-84
 first-generation, 18t-19t, 63-64
 second-generation, 18t-19t
 third-generation, 18t-19t, 78, 83-84
cephalothin, 26t-28t
chlorhexidine wash, 55
ciprofloxacin, 24t-25t, 55, 64, 84
clarithromycin, 73
clindamycin, 15-16, 26t-28t, 32-33, 63-64, 85-86
coagulase-negative *staphylococci* isolates, 17, 27t
concentration-dependent vs time-dependent, 14-17, 16t
dalfopristin-quinupristin, 16
daptomycin, 16t
diarrhea and, 18t-19t
dicloxacillin, 34-35, 55, 63-64
doxycycline, 64
drug interactions and, 18t-19t
empiric, 46t-50t
erythromycin, 15-16, 24t-28t, 32, 34-35, 63-68, 80-88
fluoroquinolones, 15-16, 16t, 18t-19t, 64, 78
fusidic acid, 20t, 26t-28t, 34-36
gentamicin, 26t-28t, 78
isoleucyl-transfer RNA inhibitors, 20t
IV, 63-68
ketolides, 16t
lauric acid monoester ointments, 34
levofloxacin, 24t-25t
lincosamides, 18t-19t, 32, 47t-50t
linezolid, 15-16, 16t
long-term, 64
macrolides, 16t, 18t-19t, 47t-50t, 68, 88
MIC measures of, 14-17
mupirocin, 20t, 26t-28t, 33-36, 73, 86

Antibiotic therapies (*continued*)

nafticillin, 63-64
neomycin, 26t-28t
oral, 18t-19t
penicillins, 16t, 18t-19t, 28t, 33, 46t-50t, 55, 63-68, 78, 88
 antipseudomonal, 78
 penicillin/ β -lactamase inhibitors, 33
 penicillin/penicillinase inhibitors, 18t-19t
 penicillinase-resistant penicillins, 46t-50t, 55, 63-64
 semisynthetic, 18t-19t, 33
pharmacokinetics of, 16
piperacillin, 78
piperacillin/tazobactam, 64
potency vs susceptibility, 24t-25t
quinolones, 83-84
resistance-related issues, 18t-20t, 24t-25t, 32
retapamulin, 20t, 26t-28t, 34, 35-38
sulfa drugs, 31-32
tetracyclines, 16-17, 16t, 18t-19t, 27t-28t, 32, 46t-50t, 64
TMP/SMX, 18t-19t, 24t-25t, 46t-50t, 64, 78, 83-84
topical agents, 17, 20t, 26t-28t
vancomycin, 16-17, 63-64
Antidepressants tricyclic, 110-112
Antifungal agents. *See also under individual drug names.*
 allylamines, 142t-143t, 162t-163t
 benzylamines, 142t-143t, 162t-163t
 butenafine, 142t-143t, 162t-163t, 169f
 ciclopirox, 168-170, 169f
 ciclopirox olamine, 142t-143t, 155-157, 156t, 161-162, 162t-163t, 168-170, 169f
 clotrimazole, 142t-143t, 162-164, 162t-163t, 165t
 econazole, 138-141, 142t-143t, 162t-163t
 fluconazole, 135-137, 136t, 169t
 griseofulvin, 135-137, 136t, 147, 153-157, 154t, 156t, 161-162
 imidazoles, 168-170, 169f
 imidazoles, topical, 138-141, 142t-143t, 161-162, 162t-163t
 itraconazole, 135-137, 136t, 153-157, 154t, 156t, 169t
 ketoconazole, 138-141, 142t-143t, 162t-163t, 169t
 miconazole, 142t-143t, 162t-163t
 naftifine, 142t-143t
 nystatin, 162-164, 165t
 oxiconazole, 140-141, 142t-143t, 162t-163t
 selenium sulfide, 169f
 sertaconazole, 142t-143t, 162t-163t
 sulconazole, 142t-143t
 terbinafine, 135-137, 136t, 142t-143t, 145-147, 169f
 tolnaftate, 161-162

Antihistamines, 110-112
 Antipseudomonal penicillins, 78
 Antipyretics, 110-112
 Antiretroviral therapy, 117-118, 118t
 Antistreptolysin. *See* ASO (antistreptolysin).
 Antiviral agents, topical vs systemic, 91-92
 acyclovir, 98-99, 100t-101t, 110-112, 111t
 antiretroviral therapy, 117-118, 118t
 cidofovir, 91-92, 100t-101t, 117-118, 118t, 129, 129t
 famciclovir, 98-99, 100t-101t, 110-112, 111t
 imiquimod, 92
 valacyclovir, 98-99, 100t-101t, 110-112, 111t
 Aphthous stomatitis, 99t
 Ascending lymphangitis, 61-62
 ASO (antistreptolysin), 67-68
Aspergillus spp, 78
 Asymptomatic viral shedding, 99-100
 Athlete's foot. *See* Tinea pedis.
 Atopic dermatitis, infected, 14t
 Azithromycin, 16-17, 73
 Aztreonam, 78

Bacitracin, 26t-28t, 73
 Bacteremia, 75
 Bacterial infections, 13-90
 abscess, 51-52
 clinical features of, 51
 diagnosis of, 51
 epidemiology and etiology of, 51
 pathogens in, 51
 reference resources for, 52
 treatment and management of, 45-52, 46f-50f
 cellulitis, 61-66
 clinical features of, 61-63, 62f
 diagnosis of, 61-63, 62f
 epidemiology and etiology of, 61-63
 pathogens in, 63
 reference resources for, 65
 treatment and management of, 45-50, 46f-50f, 63
 ecthyma and ecthyma gangrenosum, 75-78
 clinical features of, 75-78
 diagnosis of, 75-78, 76f
 ecthyma, 75-77, 76f
 ecthyma gangrenosum, 77-78
 epidemiology and etiology of, 75-78
 pathogens in, 75, 77-78
 reference resources for, 78
 treatment and management of, 45-50, 46f-50f, 75-78

Bacterial infections (*continued*)
 erysipelas, 67-70
 clinical features of, 67-68, 68f
 diagnosis of, 67-68, 68f
 epidemiology and etiology of, 67-68
 pathogens in, 67-68
 reference resources for, 69
 treatment and management of, 45-50, 46f-50f, 68
 erythrasma, 79-82
 clinical features of, 79-80, 80f
 diagnosis of, 79-80, 80f
 epidemiology and etiology of, 79-80
 pathogens in, 79-80
 reference resources for, 81
 treatment and management of, 45-50, 46f-50f, 80
 folliculitis and hot-tub folliculitis, 53-56
 clinical features of, 53-54, 54f
 diagnosis of, 53-54, 54f
 epidemiology and etiology of, 53-55
 pathogens in, 55
 reference resources for, 56
 treatment and management of, 45-50, 46f-50f, 55
 fundamentals for, 13-28
 antibiotic therapies, 13-27, 16t, 18t-20t, 21f-23f, 24t-28t
 epidemiology and etiology, 13-15, 14t-15t
 reference resources for, 17
 furuncles and carbuncles, 57-60
 clinical features of, 57-58, 58f
 diagnosis of, 57-58, 58f
 epidemiology and etiology of, 57-58
 pathogens in, 57-58
 reference resources for, 59
 treatment and management of, 45-50, 46f-50f, 58-59
 impetigo, 71-74
 clinical features of, 71-72, 72f
 diagnosis of, 71-72, 72f
 epidemiology and etiology of, 71-73
 pathogens in, 71-72, 72f
 reference resources for, 74
 treatment and management of, 45-50, 46f-50f, 73
 MRSA, 29-44
 clinical features of, 29-32, 30t, 31f
 colonization, nasal and skin, 33-35
 diagnosis of, 29-32, 30t, 31f
 epidemiology and etiology, 29-32, 30t, 31f
 pathogens in, 29-32
 reference resources for, 38-43

- Bacterial infections, MRSA (*continued*)
- topical therapies for, 35-38
 - treatment and management of, 31-33, 45-50, 46f-50f
 - perianal streptococcal disease, 87-90
 - clinical features of, 87-88, 88f
 - diagnosis of, 87-88, 88f
 - epidemiology and etiology of, 87
 - pathogens in, 87
 - reference resources for, 89
 - treatment and management of, 88
 - pitted keratolysis, 85-86
 - clinical features of, 85-86, 86f
 - diagnosis of, 85-86, 86f
 - epidemiology and etiology of, 85
 - pathogens in, 85
 - reference resources for, 86
 - treatment and management of, 45-50, 46f-50f, 85-86
 - toe-web infection, 83-84
 - clinical features of, 83
 - diagnosis of, 83
 - epidemiology and etiology of, 83
 - pathogens in, 83
 - reference resources for, 84
 - treatment and management of, 45-50, 46f-50f, 83-84
 - treatment algorithm for, 45-50, 46f-50f
- Bartonella, 182
- Basal cell carcinoma, 117t
- Basic concepts. *See* Fundamental concepts.
- Benzoic acid, 80
- Benzoyl peroxide, 80, 86
- Benzyl benzoate, 191-193t
- Benzylamines, 142t-143t, 162t-163t
- β -Hemolytic streptococci, 73-75
- β -Lactam drugs, 15-16, 46t-50t
- Bilateral inguinal lymphadenopathy, 98f
- Biologic warfare issues, 91
- Blistering distal dactylitis, 14t
- Bockhart's impetigo, 53-54
- Body lice, 182. *See also* Lice.
- Boils. *See* Furuncles and carbuncles.
- Bullous impetigo, 20t. *See also* Impetigo.
- Burns, 77
- Butenafine, 142t-143t, 162t-163t, 169f
- CA-MRSA (community-acquired methicillin-resistant *Staphylococcus aureus*), 29-30
- Calamine lotion, 110-112
- Candidiasis and *Candida* spp, 78, 131-132, 159-166
 - candidal intertrigo, 159-161, 160f
 - clinical features of, 159-161, 160f
 - diagnosis of, 159-161, 160f
 - epidemiology and etiology of, 159
 - perianal streptococcal disease and, 87
 - reference resources for, 166
 - treatment and management of, 161-165, 162t-163t, 165t
- Cantharidin, 117-118
- Capnocytophaga canimorsus*, 63-64
- Carbapenems, 16t
- Carbuncles and furuncles, 14t, 57-60
 - clinical features of, 57-58, 58f
 - diagnosis of, 57-58, 58f
 - epidemiology and etiology of, 57-58
 - pathogens in, 57-58
 - reference resources for, 59
 - treatment and management of, 45-50, 46f-50f, 58-59
- Cardiovascular disease, 62-63
- Castellani's paint, 84
- Cat bites, 63
- CDC (Centers for Disease Control and Prevention), 122-124
- Cefaclor, 18t-19t
- Cefdinir, 16, 18t-19t, 23f, 24t-25t, 46t-50t
- Cefditoren, 18t-19t
- Cefixime, 18t-19t
- Cefotaxime, 64, 84
- Cefpodoxime, 18t-19t, 24t-25t
- Cefprozil, 18t-19t, 24t-25t
- Ceftazidime, 84
- Ceftibuten, 18t-19t
- Ceftriaxone, 64
- Cefuroxime, 18t-19t, 24t-25t
- Cellulitis, 14t, 61-66, 75
 - clinical features of, 61-63, 62f
 - diagnosis of, 61-63, 62f
 - epidemiology and etiology of, 61-63
 - erysipelas and, 67-68
 - pathogens, 63
 - pathogens in, 63
 - reference resources for, 65
 - toe-web infection and, 83
 - treatment and management of, 45-50, 46f-50f, 63
- Centers for Disease Control and Prevention. *See* CDC (Centers for Disease Control and Prevention).
- Cephalexin, 18t-19t, 21f-22f, 24t-25t

Cephalosporins, 15-16, 16t, 18t-19t, 22f, 33-35, 46t, 58-59, 63-64, 73
 extended-spectrum third-generation, 18t-19t, 23f, 46t-50t, 83-84
 first-generation, 18t-19t, 63-64
 second-generation, 18t-19t
 third-generation, 18t-19t, 78, 83-84
 Cephalothin, 26t-28t
 Chancre, 99t
 Chancroid, 99t
 Chickenpox, 103, 122t
 Chickenpox (primary varicella), 103-104, 104f
 Chlamydia, 173-176, 183-185
 Chlorhexidine wash, 55
 Chronic cutaneous ulcers, 67-68
 Chronic venous insufficiency, 63-64
 Ciclopirox, 168-170, 169f
 Ciclopirox olamine, 142t-143t, 155-157, 156t, 161-162, 162t-163t, 168-170, 169f
 Cidofovir, 91-92, 100t-101t, 117-118, 118t, 129-129t
 Ciprofloxacin, 24t-25t, 55, 64, 84
 Clarithromycin, 73
 Clavulanate. *See* Amoxicillin/clavulanate.
 Clindamycin, 15-16, 26t-28t, 32-33, 63-64, 85-86
 Clinical features. *See also under individual topics.*
 of bacterial infections, 29-32, 30t, 31f, 51, 53-54, 54f, 57-58, 58f, 61-63, 62f, 67-68, 68f, 71-72, 72f, 75-80, 80f, 83, 85-86, 86f, 87-88, 88f
 abscess, 51
 cellulitis, 61-63, 62f
 ecthyma and ecthyma gangrenosum, 75-78
 erysipelas, 67-68, 68f
 erythrasma, 79-80, 80f
 folliculitis and hot-tub folliculitis, 53-54, 54f
 furuncles and carbuncles, 57-58, 58f
 impetigo, 71-72, 72f
 MRSA, 29-32, 30t, 31f
 perianal streptococcal disease, 87-88, 88f
 pitted keratolysis, 85-86, 86f
 toe-web infection, 83
 of fungal infections, 133-135, 134f-135f, 137-139, 138f-139f, 141-144, 151-153, 152f, 159-161, 160f, 167-168, 168f
 candidiasis, 159-161, 160f
 onychomycosis, 151-153, 152f
 pityriasis versicolor, 167-168, 168f
 tinea, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 of infestations and ectoparasites, 177, 182-183, 189-191, 190f-191f
 lice, 177, 182-183
 scabies, 189-191, 190f-191f

Clinical features (*continued*)
 of viral infections, 94-95, 94t, 103-107, 104f-108f, 115-116, 116f, 121-122, 126-126t, 127f
 condyloma acuminata, 126-126t, 127f
 HSV, 94-95, 94t
 MCV, 115-116, 116f
 variola, 121-122
 VZV, 103-107, 104f-108f
Clostridium difficile-associated pseudomembranous colitis, 18t-19t
 Clotrimazole, 86, 142t-143t, 162-164, 162t-163t, 165t
 CMV (cytomegalovirus), 93
 Co-trimoxazole, 34
 Coagulase-negative *staphylococci* isolates, 17, 27t
 Cold sores, 94t
 Coliform bacteria, 58
 Colitis, *Clostridium difficile*-associated, 18t-19t
 Colonization, nasal and skin, 33-35
 Community-acquired methicillin-resistant *Staphylococcus aureus*.
See CA-MRSA (community-acquired methicillin-resistant *Staphylococcus aureus*).
 Compresses, acetic acid, 84
 Compression therapy, 68
 Concentration-dependent vs time-dependent antibiotics, 14-17, 16t
 Condyloma acuminata, 117t, 125-130
 clinical features of, 126-126t, 127f
 diagnosis of, 126-127, 126t, 127f
 epidemiology and etiology of, 125
 reference resources for, 130
 treatment and management of, 127-129, 128t
 Congenital varicella infections, 104-106
 Conjunctivitis, 177
 Contact dermatitis, 109t
 Corticosteroids, 53-54, 77
Corynebacterium minutissimum, 79-80
Corynebacterium spp, 85
 Coxsackie virus, 109t
 Crab lice, *See* Public lice
 Crothamiton, 191-193t
 Cruex, 142t-143t, 162t-163t. *See also* Clotrimazole.
 Crusted scabies. *See* Scabies.
 Cryotherapy, 129
Cryptococcus, 115-116, 117t
 Curettage therapies, 117-118
 Cutaneous cryptococcosis, 117t
 Cutaneous hemorrhage, 14t
 Cutaneous ulcers, chronic, 67-68
 Cytomegalovirus. *See* CMV (cytomegalovirus).

D-zone tests, 32
Dakin's solution, 35
Dalfopristin-quinupristin, 16
Daptomycin, 16t
Decubitus ulcers, 63-64
Derimine, 142t-143t, 162t-163t. *See also* Oxiconazole.
Dermatitis, 75
Dermatitis, atopic, 14t
Dermatophilus congolensis, 85
Dermatophyte infections, 133-150. *See also* Tinea (dermatophyte infections).
Dermatoses, secondarily infected, 14t
Desonex AF, 142t-143t, 162t-163t. *See also* Clotrimazole.
Desquamation, 80f
Diabetes-related issues, 14t, 61-63, 75-79
 diabetes mellitus, 61-63, 75, 79
 diabetic foot ulcers, 14t
 diabetic wound ulcers, 14t, 62-64
Diagnoses. *See also under individual topics.*
 of bacterial infections, 29-32, 30t, 31f, 51, 53-54, 54f, 57-58, 58f, 61-63, 62f, 67-68, 68f, 75-78, 76f, 79-80, 80f, 83, 85-86, 86f, 87-88, 88f
 abscess, 51
 cellulitis, 61-63, 62f
 ecthyma and ecthyma gangrenosum, 75-78, 76f
 erysipelas, 67-68, 68f
 erythrasma, 79-80, 80f
 folliculitis and hot-tub folliculitis, 53-54, 54f
 furuncles and carbuncles, 57-58, 58f
 impetigo, 71-72, 72f
 MRSA, 29-32, 30t, 31f
 perianal streptococcal disease, 87-88, 88f
 pitted keratolysis, 85-86, 86f
 toe-web infection, 83
 of fungal infections, 133-135, 134f-135f, 137-139, 138f-139f, 141-144, 151-153, 152f, 159-161, 160f, 167-168, 168f
 candidiasis, 159-161, 160f
 onychomycosis, 151-153, 152f
 pityriasis versicolor, 167-168, 168f
 tinea, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 of infestations and ectoparasites, 177, 182-183, 189-191, 190f-191f
 lice, 177, 182-183
 scabies, 189-191, 190f-191f
 of viral infections, 94t, 95-98, 96f-98f, 99t, 104f-108f, 107-109, 109t, 116-117, 116f, 117t, 121-123, 122t, 123f, 126-127, 126t, 127f
 condyloma acuminata, 126-127, 126t, 127f

Diagnoses, of viral infections (*continued*)

 HSV, 94t, 95-98, 96f-98f, 99t
 MCV, 116-117, 116f, 117t
 variola, 121-123, 122t, 123f
 VZV, 104f-108f, 107-109, 109t
Diaper dermatitis, 87
Dicloxacillin, 34-35, 55, 63-64
Dimethylsulfoxide. *See* DMSO (dimethylsulfoxide).
Distal dactylitis, blistering, 14t
DMSO (dimethylsulfoxide), 134-135
Dog bites, 63
Down syndrome, 189
Doxycycline, 64

EBV (Epstein-Barr virus), 93, 99t
ECHO (enteric cytopathic human orphan) virus, 109t
Econazole, 84, 138-141, 142t-143t, 162t-163t
Ecostatin, 142t-143t, 162t-163t. *See also* Econazole.
Ecthyma and ecthyma gangrenosum, 14t, 75-78
 clinical features of, 75-78
 diagnosis of, 75-78, 76f
 ecthyma, 75-77, 76f
 ecthyma gangrenosum, 77-78
 epidemiology and etiology of, 75-78
 vs impetigo, 75. *See also* Impetigo.
 pathogens in, 75, 77-78
 reference resources for, 78
 treatment and management of, 45-50, 46f-50f, 75-78
Ectoparasites and infestations, 173-194
 fundamentals for, 173-176
 epidemiology and etiology, 173
 life cycle statistics, 173-174
 reference resources for, 175
 risk factors, 174
lice, 177-188
 body lice, 182
 clinical features of, 177, 182-183
 diagnosis of, 177, 182-183
 head lice, 177-182, 178f, 180t-181t
 public lice, 183-184, 183f
 reference resources, 184-187
 treatment and management of, 177-179, 180t-181t, 182-184
scabies, 189-194
 clinical features of, 189-191, 190f-191f
 diagnosis of, 189-191, 190f-191f
 epidemiology and etiology of, 189
 reference resources for, 194
 treatment and management of, 191-193, 192t-193t

- Eczema, 71-72
- Eczema herpeticum, 94t
- Edema, 61-62, 68
- Elevation therapy, 63-64
- Empiric antibiotic therapies, 46t-50t
- Endocarditis, 182
- Enteric bacilli, 14t
- Enteric cytopathic human orphan virus. *See* ECHO (enteric cytopathic human orphan) virus.
- Eosinophilic folliculitis, 53-54. *See also* Folliculitis and hot-tub folliculitis.
- Epidemic fusidic acid-resistant *Staphylococcus aureus*, 20t, 36
- Epidemiology and etiology. *See also under individual topics.*
- of bacterial infections, 29-32, 30t, 31f, 51, 53-55, 57-58, 61-63, 67-68, 71-73, 75-80, 83, 85, 87
 - abscess, 51
 - cellulitis, 61-63
 - ecthyma and ecthyma gangrenosum, 75-78
 - erysipelas, 67-68
 - erythrasma, 79-80
 - folliculitis and hot-tub folliculitis, 53-55
 - fundamentals, 13-15, 14t-15t
 - furuncles and carbuncles, 57-58
 - impetigo, 71-73
 - MRSA, 29-32, 30t, 31f
 - perianal streptococcal disease, 87
 - pitted keratolysis, 85
 - toe-web infection, 83
 - of fungal infections, 131-134, 137-138, 141, 151, 159, 167-168
 - candidiasis, 159
 - fundamentals, 131-132
 - onychomycosis, 151
 - pityriasis versicolor, 167-168
 - tinea, 133-134, 137-138, 141
 - of infestations and ectoparasites, 173, 177, 182-183, 189
 - fundamentals, 173
 - lice, 177, 182-183
 - scabies, 189
 - of viral infections, 93-94, 94t, 103, 115, 121, 125
 - condyloma acuminata, 125
 - fundamentals for, 91
 - HSV, 93-94, 94t
 - MCV, 115
 - variola, 121
 - VZV, 103
- Epidermal inclusion cysts, 117t
- Epstein-Barr virus. *See* EBV (Epstein-Barr virus).
- Ertaczo, 142t-143t, 162t-163t. *See also* Sertaconazole.
- Erysipelas, 67-70
 - clinical features of, 67-68, 68f
 - diagnosis of, 67-68, 68f
 - epidemiology and etiology of, 67-68
 - pathogens in, 67-68
 - reference resources for, 69
 - treatment and management of, 45-50, 46f-50f, 68
- Erythema, 68
- Erythrasma, 79-82
 - clinical features of, 79-80, 80f
 - diagnosis of, 79-80, 80f
 - epidemiology and etiology of, 79-80
 - pathogens in, 79-80
 - reference resources for, 81
 - treatment and management of, 45-50, 46f-50f, 80
- Erythromycin, 15-16, 24t-28t, 32, 34-35, 63-64, 68, 80, 85-86, 88
- Escherichia coli*, 14t, 78, 83
- Etiology. *See* Epidemiology and etiology.
- Exanthema, viral-like, 177
- Exelderm, 142t-143t, 162t-163t. *See also* Sulconazole.
- Extended-spectrum third-generation cephalosporins, 18t-19t, 23f, 46t-50t, 83-84
- Famciclovir, 98-99, 100t-101t, 110-112, 111t
- Familial chronic staphylococcal carriage, 57
- FDA (Food and Drug Administration), 36, 110-112
- Fever blisters, 94t
- First-generation cephalosporins, 18t-19t, 63-64
- 5-Fluorouracil, 129t
- Fluconazole, 135-137, 136t, 169t
- Fluoroquinolones, 15-16, 16t, 18t-19t, 64, 78
- Folliculitis and hot-tub folliculitis, 14t, 53-56
 - clinical features of, 53-54, 54f
 - diagnosis of, 53-54, 54f
 - epidemiology and etiology of, 53-55
 - pathogens in, 55
 - reference resources for, 56
 - treatment and management of, 45-50, 46f-50f, 55
- Food and Drug administration. *See* FDA (Food and Drug Administration).
- Foot ulcers, diabetic, 14t
- Fresh water exposure, 63-64
- Fundamental concepts, 11-12. *See also under individual topics.*
- for bacterial infections, 13-28
 - antibiotic therapies, 13-27, 16t, 18t-20t, 21f-23f, 24t-28t
 - epidemiology and etiology, 13-15, 14t-15t
 - reference resources for, 17

- Fundamental concepts (*continued*)
 for fungal infections, 131-132
 epidemiology and etiology, 131-132
 reference resources for, 132
 for infestations and ectoparasites, 173-176
 epidemiology and etiology, 173
 life cycle statistics, 173-174
 reference resources, 175
 for viral infections, 91-92
 antiviral agents, topical vs systemic, 91-92
 epidemiology and etiology, 91
- Fungal infections, 131-172
 candidiasis, 159-166
 clinical features of, 159-161, 160f
 diagnosis of, 159-161, 160f
 epidemiology and etiology of, 159
 reference resources for, 166
 treatment and management of, 161-165, 162t-163t, 165t
 fundamentals for, 131-132
 epidemiology and etiology, 131-132
 reference resources for, 132
 onychomycosis, 151-158
 clinical features of, 151-153, 152f
 diagnosis of, 151-153, 152f
 epidemiology and etiology of, 151
 reference resources for, 157-158
 treatment and management of, 153-157, 153t-154t
 pityriasis versicolor, 167-173
 clinical features of, 167-168, 168f
 diagnosis of, 167-168, 168f
 epidemiology and etiology of, 167-168
 reference resources for, 171
 treatment and management of, 168-170, 169t
 tinea, 133-150
 clinical features of, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 diagnosis of, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 epidemiology and etiology of, 133-134, 137-138, 141
 reference resources for, 148-150
 tinea capitis, 133-137, 134f-135f, 136t
 tinea corporis, 137-141, 138f-140f, 142t-143t
 tinea cruris, 141-144, 142t-143t
 tinea pedis, 142t-143t, 144-147, 145f-146f
 treatment and management of, 135-137, 136t, 139-141, 142t-143t, 144-147
- Furuncles and carbuncles, 14t, 57-60
 clinical features of, 57-58, 58f
- Furuncles and carbuncles (*continued*)
 diagnosis of, 57-58, 58f
 epidemiology and etiology of, 57-58
 pathogens, 57-58
 pathogens in, 57-58
 reference resources for, 59
 treatment and management of, 45-50, 46f-50f, 58-59
Fusarium, 78
 Fusidic acid, 20t, 26t-28t, 34-36
- Gabapentin, 110-112
 Gas-containing abscesses, 51-52
 Genital herpes, 94-98, 96f-98f, 99t-101t
 Genital warts, 126-128, 127f, 129t
 Gentamicin, 26t-28t, 78
 Genital herpes, 94t
 Gingivostomatitis, 95
 Global travel issues, 91
 Glomerulonephritis, 73
 Gonorrhea, 174, 183-185
 Gout, 62-63
 Granulocyte-macrophage colony-stimulating factor, 78
 Griseofulvin, 135-137, 136t, 147, 153-157, 154t, 156t, 161-162
- HA-MRSA (health care-associated methicillin-resistant *Staphylococcus aureus*), 29-30
Haemophilus influenzae cellulitis, 61-62
 Head lice, 177-182, 178f, 180t-181t. *See also* Lice.
 Health care-associated methicillin-resistant *Staphylococcus aureus*.
See HA-MRSA (health care-associated methicillin-resistant *Staphylococcus aureus*).
- Hematologic malignancies, 62-63, 77
 Hemorrhagic necrosis, 67-68
 Hepatotoxicity, 155
 Herpangina, 99t
 Herpes. *See also* HSV (herpes simplex virus).
 herpes febrilis, 94t
 herpes gladiatorum, 94t
 herpes labialis, 94t
 herpes progenitalis, 94t
 herpes zoster (shingles), 103
 herpetic infections, 71-72
 herpetic whitlow, 94t
 HHVs, 93
 Hidradenitis suppurativa, 51
 Histoplasmosis, 117t
 HIV (human immunodeficiency virus), 14t, 53-54, 174-178

- Hot-tub folliculitis and folliculitis, 53-56
 clinical features of, 53-54, 54f
 diagnosis of, 53-54, 54f
 epidemiology and etiology of, 53-55
 pathogens, 55
 pathogens in, 55
 reference resources for, 56
 treatment and management of, 45-50, 46f-50f, 55
- HPV (human papillomavirus), 91, 125-129, 174. *See also* Condyloma acuminata.
- HSV (herpes simplex virus), 93-102
 clinical features of, 94-95, 94t
 diagnosis of, 94t, 95-98, 96f-98f, 99t
 epidemiology and etiology of, 93-94, 94t
 vs HHVs, 93-98, 94t
 infestations and ectoparasites and, 174
 reference resources for, 102
 treatment and management of, 98-101, 100t-101t
- Human herpes viruses (HHVs). *See* Herpes; HSV (herpes simplex virus).
- Human immunodeficiency virus. *See* HIV (human immunodeficiency virus).
- Human papillomavirus. *See* HPV (human papillomavirus).
- Hyperhidrosis, 53-54, 83, 85-86
- IBD (inflammatory bowel disease), 87
- Imidazoles, topical, 138-141, 142t-143t, 161-162, 162t-163t, 168-170, 169f
- Imiquimod, 92, 118t, 127-129, 128t-129t, 129
- Immunotherapies, 118t
- Impetigo, 14t, 71-74
 Bullous vs nonbullous, 20t, 71-72
 clinical features of, 71-72, 72f
 diagnosis of, 71-72, 72f
 vs ecthyma, 75. *See also* Ecthyma and ecthyma gangrenosum.
 epidemiology and etiology of, 71-73
 pathogens in, 71-72, 72f
 reference resources for, 74
 treatment and management of, 45-50, 46f-50f, 73
- Incision and drainage therapies, 51-52, 58
- Indications, table of, 14t
- Infectious Disease Society of America. *See* ISDA (Infectious Disease Society of America) guidelines.
- Infestations and ectoparasites, 173-194
 fundamentals for, 173-176
 epidemiology and etiology, 173
 life cycle statistics, 173-174
- Infestations and ectoparasites (*continued*)
 reference resources, 175
 risk factors, 174
- lice, 177-188
 body lice, 182
 clinical features of, 177, 182-183
 diagnosis of, 177, 182-183
 epidemiology and etiology of, 177, 182-183
 head lice, 177-182, 178f, 180t-181t
 pubic lice, 183-184, 183f
 reference resources for, 184-187
 treatment and management of, 177-179, 180t-181t, 182-184
- scabies, 189-194
 clinical features of, 189-192, 190f-191f
 diagnosis of, 189-191, 190f-191f
 epidemiology and etiology of, 189
 reference resources for, 194
 treatment and management of, 191-193, 192t-193t
- Inflammatory bowel disease. *See* IBD (inflammatory bowel disease).
- Insect bites, 71-72, 75, 109t
- Interferon-alpha, 127-129, 128t-129t
- Intertrigo, 79, 159-160
- Intravenous. *See* IV (intravenous).
- Introductory concepts. *See* Fundamental concepts.
- Inverse psoriasis, 79
- Iodine tincture, 117-118
- ISDA (Infectious Disease Society of America) guidelines, 32-33
- Isolecyl-transfer RNA inhibitors, 20t
- Itraconazole, 135-137, 136t, 153-157, 154t, 156t, 169t
- IV (intravenous), 30t, 62-63
 antibiotic therapies, 63-68
 catheters, 77
 drug use, 30t, 62-63
- Jock itch. *See* Tinea cruris.
- Keratoacanthoma, 117t
- Keratolysis, pitted. *See* Pitted keratolysis.
- Ketoconazole, 138-141, 142t-143t, 162t-163t, 169t
- Ketolides, 16t
- Klebsiella* spp, 14t
- Knock-down resistance, 179-180
- KOH (potassium hydroxide), 134-135, 140f, 146f
- Kytococcus sedentarius*, 85
- Lactic acid, 117-118
- Lamisil and Lamisil AT, 142t-143t, 162t-163t. *See also* Terbinafine.

- Lauric acid monoester ointments, 34
- Leukemia, 184
- Levofloxacin, 24t-25t
- Lice, 177-188, 180t-181t, 182-184
body lice, 182
clinical features of, 177, 182-183
diagnosis of, 177, 182-183
epidemiology and etiology of, 177, 182-183
head lice, 177-182, 178f, 180t-181t
pubic lice, 183-184, 183f
reference resources for, 184-187
treatment and management of, 177-179, 180t-181t, 182-184
- Life cycle statistics, ectoparasites, 173-174. *See also* Ectoparasites and infestations.
- Lincosamides, 18t-19t, 32, 47t-50t
- Lindane, 180t-181t, 184, 192t-193t
- Linezolid, 15-16, 16t
- Lipodermatosclerosis, 62-63
- Liquid nitrogen, 117-118
- Long-term antibiotic therapies, 64
- Loprox, 142t-143t. *See also* Ciclopirox olamine.
- Lotrimin and Lotrimin AF, 142t-143t, 162t-163t. *See also* Clotrimazole.
- Low-dose TCAs (tricyclic antidepressants), 110-112. *See also* TCAs (tricyclic antidepressants).
- Lupus erythematosus, 67-68
- Lymphadenopathy, 75, 98f, 122t, 177
- Lymphangitis, 75
- Lymphangitis, ascending, 61-62
- Lymphoedema, 67-68
- Maceration, 83
- Macrolides, 18t-19t, 47t-50t, 68, 88
- Majocchi's granuloma, 138-139
- Malassezia*, 132, 167-170
- Malathion, 178-180, 180t-181t
- Malnutrition, 61-62
- Management and treatment. *See* Treatment and management.
- Macrolides, 16t
- MCV (molluscum contagiosum virus), 115-120, 126t
clinical features of, 115-116, 116f
diagnosis of, 116-117, 116f, 117t
epidemiology and etiology of, 115
reference resources for, 118-119
treatment and management of, 117-118, 118t
- Mentax, 142t-143t, 162t-163t. *See also* Butenafine.
- Methicillin-resistant *Staphylococcus aureus*. *See* MRSA (methicillin-resistant *Staphylococcus aureus*).
- Methicillin-susceptible *Staphylococcus aureus*. *See* MSSA (methicillin-susceptible *Staphylococcus aureus*).
- Metronidazole, 64
- MIC (minimum inhibitory concentration) measures, 14-17
- Micatin, 142t-143t, 162t-163t. *See also* Miconazole.
- Miconazole, 80, 86, 142t-143t, 162t-163t
- Micozole, 142t-143t, 162t-163t. *See also* Miconazole.
- Micrococcus sedentarius*, 85
- Moist heat therapies, 58
- Molluscum contagiosum virus. *See* MCV (molluscum contagiosum virus).
- Monistat, 142t-143t, 162t-163t. *See also* Miconazole.
- Monkeypox, 122t
- Mononucleosis-like syndrome, 95
- Morganella morganii*, 83
- MRSA (methicillin-resistant *Staphylococcus aureus*), 29-44, 46t-50t, 55-56, 58-59
CA-MRSA, 29-30, 49t
clinical features of, 29-32, 30t, 31f
colonization, nasal and skin, 33-35
diagnosis of, 29-32, 30t, 31f
epidemiology and etiology, 29-32, 30t, 31f
HA-MRSA, 29-30
pathogens in, 29-32
reference resources for, 38-43
topical therapies for, 35-38
treatment and management of, 31-33, 45-50, 46f-50f
antibiotic therapies, 18t-19t, 26t-27t
- MSSA (methicillin-susceptible *Staphylococcus aureus*), 18t-19t, 26t-27t
- Mucosal candidiasis, 160-162
- Mupirocin, 20t, 26t-28t, 33-36, 73, 86
- Mycelex, 142t-143t, 162t-163t. *See also* Clotrimazole.
- Myfungar, 142t-143t, 162t-163t. *See also* Oxiconazole.
- Nafcillin, 63-64
- Naftifine, 142t-143t
- Naftin, 142t-143t. *See also* Naftifine.
- Nail fungal infections. *See* Onychomycosis.
- Nasal colonization, 33-35
- Necrosis, 68
- Neisseria meningitidis*, 78
- Neomycin, 26t-28t
- Neonatal herpes, 100t-101t
- Nephritis, 73

Neurilemmoma, 117t
Neutropenia, 75, 77-78
Nickerson's medium, 161
Nizoral and Nizoral AD, 162t-163t. *See also* Ketoconazole.
Norwegian scabies. *See* Scabies.
Nystatin, 161-164, 165t

Obesity, 79
Occipital lymphadenopathy, 133-134
Oceral, 142t-143t, 162t-163t. *See also* Oxiconazole.
Okinazole, 142t-143t, 162t-163t. *See also* Oxiconazole.
Onychomycosis, 151-158
 clinical features of, 151-153, 152f
 diagnosis of, 151-153, 152f
 epidemiology and etiology of, 151
 reference resources for, 157-158
 treatment and management of, 153-157, 153t-154t
Oral antibiotic therapies, 18t-19t. *See also* Antibiotic therapies.
Oral candidiasis, 99t, 160-162
Oral labial herpes, 96-99, 96f, 99t-101t
Orthopedic pins, 68
Overviews and summaries. *See* Fundamental concepts.
Oxiconazole, 140-141, 142t-143t, 162t-163t
Oxistat, 142t-143t, 162t-163t. *See also* Oxiconazole.
Oxizole, 162t-163t. *See also* Oxiconazole.

Pap (Papaniculou) smears, 129
Paronychia, acute, 14t
Pathogens, 29-32, 51, 55, 57-58, 63, 67-68, 71-72, 72f, 75, 77-80,
 83, 85, 87. *See also under individual pathogens.*
 in abscess, 51
 Actinomyces spp, 85
 Aeromonas hydrophila, 63-64, 78
 Aspergillus spp, 78
 Candida spp, 78, 131-132, 159-166
 Capnocytophaga canimorsus, 63-64
 in cellulitis, 63
 Clostridium difficile, 18t-19t
 Corynebacterium minutissimum, 79-80
 Corynebacterium spp, 85
 Cryptococcus, 115-116, 117t
 Dermatophilus congolensis, 85
 in ecthyma and ecthyma gangrenosum, 75, 77-78
 in erysipelas, 67-68
 in erythrasma, 79-80
 Escherichia coli, 14t, 78, 83
 in folliculitis and hot-tub folliculitis, 55

Pathogens (*continued*)
in furuncles and carbuncles, 57-58
Haemophilus influenzae, 61-62
in impetigo, 71-72, 72f
Klebsiella spp, 14t
Kytococcus sedentarius, 85
Malassezia, 132, 167-170
Micrococcus sedentarius, 85
Morganella morganii, 83
MRSA, 29-44, 46t-50t, 55-56, 58-59
MSSA, 18t-19t, 26t-27t
Neisseria meningitidis, 78
in perianal streptococcal disease, 87
Phthirus pubis, 184
in pitted keratolysis, 85
Pityrosporum, 131-132, 167-170
Proteus mirabilis, 83
Serratia marcescens, 78
Streptococcus agalactiae, 14t, 28t
Streptococcus pyogenes, 14t, 18t-19t, 22f, 28t, 36-38, 63-64, 75,
 87-88
 table of, 14t
 in toe-web infection, 83
Vibrio spp, 63-64
Vibrio vulnificus, 63-64
Pearly penile papules, 126t
Pediculosis capitis, 71-72
Penicillins, 16t, 18t-19t, 28t, 63-68, 78, 88
 allergies, 63-64
 antipseudomonal, 78
 penicillin/β-lactamase inhibitors, 33
 penicillin/penicillinase inhibitors, 18t-19t
 penicillinase-resistant penicillins, 46t-50t, 55, 63-64
 semisynthetic, 18t-19t, 33
Penicilliosis, 117t
Permethrin, 178-180, 180t-181t
Perianal erythema, 87-88, 88f
Perianal pruritus, 87
Perianal streptococcal disease, 87-90
 clinical features of, 87-88, 88f
 diagnosis of, 87-88, 88f
 epidemiology and etiology of, 87
 pathogens in, 87
 reference resources for, 89
 treatment and management of, 88
Peripheral vascular disease, 61-62
Perleche, 160-162

- Permethrin, 182, 184, 191-193t
- Pharmacokinetics, antibiotic therapies, 16
- Pharyngitis-like syndrome, 95, 99t
- Phenol, 117-118
- Photosensitivity, 18t-19t
- Phthirus pubis*, 184
- Pinworm disease, 87
- Piperacillin, 78
- Piperacillin/tazobactam, 64
- Pitted keratolysis, 85-86
 - clinical features of, 85-86, 86f
 - diagnosis of, 85-86, 86f
 - epidemiology and etiology of, 85
 - pathogens in, 85
 - reference resources for, 86
 - treatment and management of, 45-50, 46f-50f, 85-86
- Pityriasis versicolor, 167-173
 - clinical features of, 167-168, 168f
 - diagnosis of, 167-168, 168f
 - epidemiology and etiology of, 167-168
 - reference resources for, 171
 - treatment and management of, 168-170, 169t
- Pityrosporum*, 131-132, 167-170
- Podophyllin, 117-118, 129t
- Podophyllotoxin, 117-118, 129t
- Poison ivy, 71-72
- Polyenes, topical, 161-162
- Postmastectomy cellulitis, 61-62
- Poststreptococcal glomerulonephritis, 75, 77, 88
- Potassium chloride, 167-168
- Potassium hydroxide. *See* KOH (potassium hydroxide).
- Poxviruses, 91
- Primary syphilis, 99t
- Primary varicella (chickenpox), 103-104, 104f
- Proteus mirabilis*, 83
- Proximal onychomycosis, 151-153, 152f. *See also* Onychomycosis.
- Pruritus, 189
- Pseudomonas aeruginosa*, 55-56, 63-64, 77-78, 83
- Psoriasis, 87
- Psoriasis, inverse, 79
- Pubic lice, 183-184, 183f. *See also* Lice.
- Punched out ulcers, 75
- Pyoderma, 117t
- Pyogenic granuloma, 117t
- Pyrethrins, 178-180, 180t-181t
- Pyoderma gangrenosum, 77
- Pyonychia, 160-161
- Quinolones, 83-84
- Recurrent furunculosis, 59
- Reference resources. *See also under individual topics.*
 - for bacterial infections, 38-43, 52, 56, 59, 65, 69, 74, 78, 81, 84, 86, 89
 - abscess, 52
 - cellulitis, 65
 - ecthyma and ecthyma gangrenosum, 78
 - erysipelas, 69
 - erythrasma, 81
 - folliculitis and hot-tub folliculitis, 56
 - fundamental concepts, 17
 - furuncles and carbuncles, 59
 - impetigo, 74
 - MRSA, 38-43
 - perianal streptococcal disease, 89
 - pitted keratolysis, 86
 - toe-web infection, 84
 - for fundamental concepts
 - for fungal infections, 132, 148-150, 157-158, 166, 171
 - candidiasis, 166
 - fundamentals, 132
 - onychomycosis, 157-158
 - pityriasis versicolor, 171
 - tinea, 148-150
 - for infestations and ectoparasites, 175, 184-187, 194
 - fundamental, 175
 - lice, 184-187
 - scabies, 194
 - for viral infections, 102, 113, 118-119, 124, 130
 - condyloma acuminata, 130
 - HSV, 102
 - MCV, 118-119
 - variola, 124
 - VZV, 113
- Refractory infections, 46t-50t
- Regional adenopathy, 67-68
- Retapamulin, 20t, 26t-28t, 34, 35-38
- Ringworm. *See* Tinea corporis.
- Sabouraud's medium, 161
- Salicylic acid, 80, 117-118, 129
- Saltwater exposure, 63-64
- Scabies, 189-194
 - clinical features of, 189-191, 190f-191f
 - diagnosis of, 189-191, 190f-191f

- Scabies (*continued*)
 epidemiology and etiology of, 189
 impetigo and, 71-72
 reference resources for, 194
 treatment and management of, 191-193, 192t-193t
- Seborrheic dermatitis, 79
- Seborrheic scale, 177
- Second-generation cephalosporins, 18t-19t. *See also* Cephalosporins.
- Secondary infections, 14t, 46t
 dermatosis, 14t
 traumatic dermatitis, 46t
 traumatic lesions, 46t
- Selenium sulfide, 169f
- Semisynthetic penicillins, 18t-19t, 33
- Sepsis, 77, 83
- Serratia marcescens*, 78
- Sertaconazole, 142t-143t, 162t-163t
- Sexually-transmitted diseases. *See* STDs (sexually-transmitted diseases).
- Shingles (herpes zoster), 103
- Syphilis, 122t
- Silver nitrite, 117-118
- Skin and skin-structure infections. *See also under individual topics.*
 bacterial infections, 13-90
 abscess, 51-52
 cellulitis, 61-66
 ecthyma and ecthyma gangrenosum, 75-78
 erysipelas, 67-70
 erythrasma, 79-82
 folliculitis and hot-tub folliculitis, 53-56
 fundamentals for, 13-28
 furuncles and carbuncles, 57-60
 impetigo, 71-74
 MRSA, 29-44
 perianal streptococcal disease, 87-90
 pitted keratolysis, 85-86
 toe-web infection, 83-84
 treatment algorithm for, 45-50
 fundamental concepts for, 11-12
 fungal infections, 131-172
 candidiasis, 159-166
 fundamentals for, 131-132
 onychomycosis, 151-158
 pityriasis versicolor, 167-173
 tinea, 133-150
- Skin and skin-structure infections (*continued*)
 infestations and ectoparasites, 173-194
 fundamentals for, 173-176
 lice, 177-188
 scabies, 189-194
 viral infections, 91-130
 condyloma acuminata, 125-130
 fundamentals for, 91-92
 HSV, 93-102
 MCV, 115-120
 variola, 121-124
 VZV, 103-114
- Skin colonization, 33-35
- Sloughing, 14t
- Smallpox, 109t, 121-124. *See also* Variola.
- SMX (sulfamethoxazole). *See* TMP/SMX (trimethoprim/sulfamethoxazole).
- Soaps, antibacterial, 80
- Sodium fusidate ointment, 80
- Spectazole, 142t-143t, 162t-163t. *See also* Econazole.
- SSSIs. *See* Skin and skin-structure infections.
- Staphylococcal scalded-skin syndrome, 73
- Staphylococcus aureus*, 14t, 17-25, 18t-20t, 22f, 24t-26t, 32-38, 51, 55-58, 63-64, 73, 78, 87-88
 isolates, 17, 26t
 MRSA, 29-44, 46t-50t, 55-56, 58-59
 MSSA, 18t-19t, 26t-27t
- Stasis dermatitis, 62-64
- STDs (sexually-transmitted diseases), 147, 174-185
- Stevens-Johnson syndrome, 18t-19t, 99t
- Streptococcus agalactiae*, 14t, 28t
- Streptococcus pyogenes*, 14t, 18t-19t, 22f, 28t, 36-38, 63-64, 75, 87-88
- Streptozyme, 67-68
- Sulconazole, 142t-143t, 162t-163t
- Sulcosyn, 142t-143t, 162t-163t. *See also* Sulconazole.
- Sulfa drugs, 31-32
- Sulfamethoxazole. *See* TMP/SMX (trimethoprim/sulfamethoxazole).
- Summaries and overviews. *See* Fundamental concepts.
- Superficial cellulitis, 14t. *See also* Cellulitis.
- Superficial onychomycosis, 151-153, 153f. *See also* Onychomycosis.
- Superficial thrombophlebitis, 62-63
- Sycosis vulgaris, 53-54
- Syphilitic condyloma, 126t
- Syphilis, 99t, 174

Tape stripping, 117-118, 167-168
 Tazobactam. *See* Piperacillin/tazobactam.
 TCAs (tricyclic antidepressants), 110-112
 Tepid bath therapy, 110-112
 Terbinafine, 135-137, 136t, 142t-143t, 145-147, 153-157, 154t, 156t, 162t-163t, 169f
 Tetracyclines, 16-17, 16t, 18t-19t, 27t-28t, 32, 46t-50t, 64
 Third-generation cephalosporins, 18t-19t, 78, 83-84
 Thrombophlebitis, superficial, 62-63
 Thrush, 160-164, 165t
 Time-dependent vs concentration-dependent antibiotics, 14-17, 16t
 Tinea capitis, 133-137, 134f-135f, 136t
 Tinea corporis, 137-141, 138f-140f, 142t-143t
 Tinea cruris, 141-144, 142t-143t
 Tinea (dermatophyte infections), 133-150
 cellulitis and, 61-62
 clinical features of, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 diagnosis of, 133-135, 134f-135f, 137-139, 138f-139f, 141-144
 epidemiology and etiology of, 133-134, 137-138, 141
 erythrasma and, 79
 reference resources for, 148-150
 tinea capitis, 133-137, 134f-135f, 136t
 tinea corporis, 137-141, 138f-140f, 142t-143t
 tinea cruris, 141-144, 142t-143t
 tinea pedis, 83, 142t-143t, 144-147, 145f-146f
 tinea versicolor. *See* Pityriasis versicolor.
 toe-web infection and, 83
 treatment and management of, 135-137, 136t, 139-141, 142t-143t, 144-147
 Tinea incognito, 137-140, 139f
 Tinea pedis, 83, 142t-143t, 144-147, 145f-146f
 TMP/SMX (trimethoprim/sulfamethoxazole), 18-19t, 24t-25t, 46t-50t, 64, 78, 83-84
 Toe-web infection, 83-84
 cellulitis and, 61-62
 clinical features of, 83
 diagnosis of, 83
 epidemiology and etiology of, 83
 pathogens in, 83
 reference resources for, 84
 treatment and management of, 45-50, 46f-50f, 83-84
 Tolnaftate, 80, 161-162
 Topical agents, antibiotic therapies, 20t, 26t-28t. *See also* Antibiotic therapies.
 Topical antibiotic therapies, 17

Treatment and management
 of bacterial infections, 31-33, 45-52, 46f-50f, 55, 58-59, 63, 68, 73, 75-78, 80, 83-86, 88
 abscess, 45-52, 46f-50f
 algorithm for, 45-50, 46f-50f
 cellulitis, 45-50, 46f-50f, 63
 ecthyma and ecthyma gangrenosum, 45-50, 46f-50f, 75-78
 erysipelas, 45-50, 46f-50f, 68
 erythrasma, 45-50, 46f-50f, 80
 folliculitis and hot-tub folliculitis, 45-50, 46f-50f, 85
 furuncles and carbuncles, 45-50, 46f-50f, 58-59
 impetigo, 45-50, 46f-50f, 73
 MRSA, 31-33, 45-50, 46f-50f
 perianal streptococcal disease, 88
 pitted keratolysis, 45-50, 46f-50f, 85-86
 toe-web infection, 45-50, 46f-50f, 83-84
 of fungal infections, 135-137, 136t, 139-141, 142t-143t, 144-147, 153-157, 153t-154t, 161-165, 162t-163t, 165t, 168-170, 169t
 candidiasis, 161-165, 162t-163t, 165t
 onychomycosis, 153-157, 153t-154t
 pityriasis versicolor, 168-170, 169t
 tinea, 135-137, 136t, 139-141, 142t-143t, 144-147
 of infestations and ectoparasites, 177-179, 180t-181t, 182-184, 191-193, 192t-193t
 lice, 177-179, 180t-181t, 182-184
 scabies, 191-193, 192t-193t
 of viral infections, 98-101, 100t-101t, 110-112, 111t, 117-118, 118t, 123, 127-129, 128t
 condyloma acuminata, 127-129, 128t
 HSV, 98-101, 100t-101t
 MCV, 117-118, 118t
 variola, 123
 VZV, 110-112, 111t
 Tretinoin creams and gels, 117-118
 Trichomoniasis, 174
Trichophyton tonsurans, 133-134
 Tricyclic antidepressants. *See* TCAs (tricyclic antidepressants).
 Trimethoprim/sulfamethoxazole, 18t-19t, 24t-25t, 64
 Tzanck smears, 97-98

 Uncomplicated skin and skin-structure infections. *See also under individual topics.*
 bacterial infections, 13-90
 abscess, 51-52
 cellulitis, 61-66
 ecthyma and ecthyma gangrenosum, 75-78
 erysipelas, 67-70

Uncomplicated skin and skin-structure infections (*continued*)

erythrasma, 79-82
folliculitis and hot-tub folliculitis, 53-56
fundamentals for, 13-28
furuncles and carbuncles, 57-60
impetigo, 71-74
MRSA, 29-44
perianal streptococcal disease, 87-90
pitted keratolysis, 85-86
toe-web infection, 83-84
treatment algorithm for, 45-50
fundamental concepts for, 11-12
fungal infections, 131-172
candidiasis, 159-166
fundamentals for, 131-132
onychomycosis, 151-158
pityriasis versicolor, 167-173
tinea, 133-150
infestations and ectoparasites, 173-194
fundamentals for, 173-176
lice, 177-188
scabies, 189-194
viral infections, 91-130
condyloma acuminata, 125-130
fundamentals for, 91-92
HSV, 93-102
MCV, 115-120
variola, 121-124
VZV, 103-114
Urinary catheters, 77
USSSIs. *See* Uncomplicated skin and skin-structure infections.

Vaccinia, 121
Valacyclovir, 98-99, 100t-101t, 110-112, 111t
Vancomycin, 16-17, 63-64
Varicella, 122t
Varicella zoster virus. *See* VZV (varicella zoster virus).
Variola, 121-124
clinical features of, 121-122
diagnosis of, 121-123, 122t, 123f
epidemiology and etiology of, 121
reference resources for, 124
treatment and management of, 123
Variola minor, 122
Verruca vulgaris, 117t
Vesicular viral exanthema, 109t
Vibrio spp, 63-64

Vibrio vulnificus, 63-64
Violaceous bullae, 14t
Viral exanthems, 91
Viral infections, 91-130
condyloma acuminata, 125-130
clinical features of, 126-126t, 127f
diagnosis of, 126-127, 126t, 127f
epidemiology and etiology of, 125
reference resources for, 130
treatment and management of, 127-129, 128t
fundamentals for, 91-92
antiviral agents, topical vs systemic, 91-92
epidemiology and etiology, 91
HSV, 93-102
clinical features of, 94-95, 94t
diagnosis of, 94t, 95-98, 96f-98f, 99t
epidemiology and etiology of, 93-94, 94t
reference resources for, 102
treatment and management of, 98-101, 100t-101t
MCV, 115-120
clinical features of, 115-116, 116f
diagnosis of, 116-117, 116f, 117t
epidemiology and etiology of, 115
reference resources for, 118-119
treatment and management of, 117-118, 118t
variola, 121-124
clinical features of, 121-122
diagnosis of, 121-123, 122t, 123f
epidemiology and etiology of, 121
reference resources for, 124
treatment and management of, 123
VZV, 103-114
clinical features of, 103-107, 104f-108f
diagnosis of, 104f-108f, 107-109, 109t
epidemiology and etiology of, 103
reference resources for, 113
treatment and management of, 110-112, 111t
Viridans streptococci, 28t
VZV (varicella zoster virus), 103-114
clinical features of, 103-107, 104f-108f
diagnosis of, 104f-108f, 107-109, 109t
epidemiology and etiology of, 103
vs HSV, 93
reference resources for, 113
treatment and management of, 110-112, 111t

Western blot technique, 95-96
Whitfield's ointment, 80
WHO (World Health Organization), 121
Wood's light, 79
World Health Organization. *See* WHO (World Health Organization).
Wound ulcers, diabetic, 14t

Yeast infections, 18t-19t

Zeasorb AF, 142t-143t, 162t-163t. *See also* Miconazole.
Zoster, 62-63